Clinical Trial

External Body Weight Effects on Body Weight in Adults With Grade II and III Obesity

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 1, 2024 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
Obesity is a growing problem in industrialized societies. This condition is associated with an increase in metabolic and cardiovascular diseases. Its cause is multifactorial, influenced by the environment, excessive calorie consumption, insufficient physical activity, sedentary lifestyle and alterations in energy metabolism. In this context, the hormone leptin, responsible for regulating appetite and body weight, presents resistance in people with obesity, altering the metabolic balance. Recent research has explored the concept of the "gravitostat", a system that responds to the mechanical stimulus of standing upright, as a promising approach in the regulation of body weight. Animal and human studies have shown positive results in weight loss and body recomposition using this system. However, more research is needed to evaluate the clinical applicability and effectiveness of the gravitostat in the management of obesity. For this reason, the present study is proposed, with a prospective longitudinal controlled design in the use of external body weight (where the patients are their own control: intrasubject controlled study) during 4 weeks, with a previous control period of 4 weeks and a follow-up of 4 weeks. The proposed objectives are to analyze the effectiveness of the use of external weight in the regulation of body weight, body composition and analytical parameters in people with grade II and III obesity. In this way, to analyze the clinical applicability of the gravitostat in the management of patients with this metabolic pathology.
Trial Details
NCT Number NCT06619028
Lead Sponsor Escoles Universitaries Gimbernat
Collaborators: Corporacion Parc Tauli
Conditions Obesity Prevention, Obesity
Enrollment 24 participants
Start Date 2024-10-01
Primary Completion 2025-07-01 (estimated)
Study Completion 2025-07-01 (estimated)
Updated on ClinicalTrials.gov 2024-10-01